EVOKE PHARMA, INC. (NASDAQ:EVOK) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On May 14, 2018, Evoke Pharma, Inc. issued a press release announcing its financial results for the first quarter of 2018.A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instructions B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Evoke Pharma Inc Exhibit
EX-99.1 2 evok-ex991_8.htm EX-99.1 evok-ex991_8.htm Exhibit 99.1     Investor Contact: The Ruth Group Tram Bui Tel: 646-536-7035 [email protected]             Evoke Pharma Reports First Quarter 2018 Results and Highlights   The Company will hold a conference call following submission of Gimoti NDA     • NDA submission for Gimoti™ on track for second quarter of 2018   • Announced discovery of sex-based pharmacokinetic differences for Gimoti   • Waiver of the PDUFA fee for Gimoti NDA granted by FDA   • Cash runway extended into April 2019   SOLANA BEACH,…
To view the full exhibit click here

About EVOKE PHARMA, INC. (NASDAQ:EVOK)

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.